MOD GRF 1-29
Mod GRF 1-29 (also referred to as simply Mod GRF) is an injectable peptide used to increase GH production. The principal use of Mod GRF 1-29 is to provide increased GH levels, which also results in increased IGF-1 levels. An increase in these levels can aid fat loss and in some instances can aid muscle gain as well. Generally, Mod GRF 1-29 is used as part of alternate plan to using GH, and only rarely is combined with GH. Mod GRF 1-29 generally is not used alone, but most commonly is used in combination with a peptide of the GHRP class, such as GHRP-2, GHRP-6, Hexarelin, or Ipamorelin.
Tetrasubstituded GRF 1-29
2mg MOD GRF 1-29 (VIAL)
About MOD GRF 1-29
Even though in bodybuilding circles we don’t hear much about MOD GRF, this doesn’t mean that this peptide does not have its uses. In fact, anti-aging and hormone replacement clinics have been prescribing it for years because it works as a clean GHRH.
Mod GRF 1-29 is a synthetic growth hormone secretagogue from the growth hormone releasing hormone family. These compounds are based on GHRH, a natural peptide hormone that signals the release of GH from the pituitary gland. GHRH is one of two primary positive regulators of GH secretion in humans, acting together with ghrelin. Both hormones are the subjects of extensive drug development. With GHRH, though it can be synthesized as a drug product, it is not really adequate as a therapeutic agent. It is too short acting. Mod GRF 1-29 is potentially more viable. It is a shortened, modified form of GHRH that is more resistant to enzymatic cleavage. It has a longer half-life, and is a more potent agent for increasing serum GH and IGF-1 levels.
Mod GRF 1-29 is almost identical to CJC-1295 in structure. It differs only by the lack of an attached maleimidoproprionic acid group, also known as Drug Affinity Complex (DAC). DAC temporarily binds CJC-1295 to serum albumin, greatly extending its half-life. This is why Mod GRF 1-29 is also commonly called "CJC-1295 without DAC." It simply lacks this complex. Because of this, Mod GRF 1-29 is much shorter acting. It has a half-life measured in minutes or hours instead of days. Whereas CJC-1295 can be injected weekly, Mod GRF 1-29 is usually injected several times daily. Otherwise, these two are the same drug... the same active peptide. In the fitness community, Mod GRF 1 -29 is used for the support of muscle growth and fat loss, as well as its potential anti-aging properties.
Much of what else can be said of CJC-1295 should hold true for Mod GRF 1-29. Most basically, this is to be considered a "selective" GH secretagogue. It displays a great deal of specificity for growth hormone release, and is unlikely to significantly alter levels of cortisol, prolactin, LH (luteinizing hormone), or TSH (thyroid stimulating hormone). Likewise, significant spillover side effects pertaining to these hormones, which are common to many drugs of the GHRP class that mimic ghrelin, are unlikely with Mod GRF 1-29.That isn't to say the Mod GRF 1-29 and CJC-1295 are interchangeable. The short acting nature of Mod GRF 1-29 might make it more useful for fostering acute spikes in GH/IGF-1, when used alongside a similarly short acting GHRP
The problem for the bodybuilder or athlete is that it has a very short half-life of about ten minutes. Despite its short window, it does bind quite effectively to the pituitary receptors. The other main down side associated with its very short half life is that it is quickly broken down by blood enzymes within minutes. This is why a GHRH peptide with a half life of 30 minutes or longer is desirable (such as GHRP-2, GHRP-6, Hexarelin, or Ipamorelin), since it will survive the blood enzyme death and allow it to circulate the body looking for hormone receptors to bind to.
MOD GRF 1-29 effects
Positive effects of MOD GRF 1-29 include increased lean body mass, reduced fat, increased strength, improved recovery, better sleep, strengthening of the heart, enhancing of the immune system and increases IGF-1 production.
While the ability of MOD GRF to act is short, it still promotes all of these factors, not to mention it also has the ability to increase protein synthesis, promote growth of all internal organs with the exception of the brain and promote and increase in liver glucogenesis.
Despite its tiny half life, MOD GRF’s ability to increase IGF-1 in the blood stream will only further increase the function of the metabolism and the growth of new cells in muscles, bones and organs. MOD GRF is heavily pushed by HRT clinics and is often referred to as the anti-aging peptide since it is very good at reversing some of the effects of aging in adults.
The fact that doctors can legally prescribe this peptide helps HRT clinics further their legitimacy and also offer a viable and more cost effective solution to prescribing exogenous HGH.
MOD GRF 1-29 administration
Mod GRF 1-29 is provided in vials containing 2 mg of lyophylized powder. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water.
Injection may be subcutaneous, intramuscular, or intravenous, according to personal preference. If desired, peptide solutions from other vials, such as a vial of a GHRP product, may also be drawn into the same syringe. This reduces the total number of injections required.
Recommend dosage is 100 mcg Mod GRF at a time, simultaneous with injection of a GHRP. For maximum effect, dosing is preferably three times per day at times of low blood sugar, for example about 30 minutes before a meal, but where use is ongoing, a common use is once per day prior to sleep.
MOD GRF 1-29 side effects
Common side effects to Mod GRF 1-29 include flushing, warmth, dizziness, and transient hypotension following injection. Other common side effects include sleepiness, headache, diarrhea, nausea, and abdominal pain. Also frequently reported are adverse effects typically associated with other types of growth hormone therapy, such as water retention (edema), joint pain (arthralgias), carpal tunnel syndrome, and numbness or tingling in the extremities. Note that the incidence of GH-related side effects tends to be lower with GHRP therapy as compared to traditional hGFI. This is because GFI/IGF-1 release is subject to the limits of endogenous synthesis, and as such the drug is less amenable to overdosing.
The subcutaneous administration of this drug may cause redness, itching, pain, or lumps at the site of injection.